Carrick Therapeutics is now ready to scale the company and is looking for new partners with compounds that target the key pathways in cancer progression ... A first-in-class oral CDK7 inhibitor ...

The initial programs target CDK7/9, GSPT1, CK1a ... Given the central role of p53, Myc, and MCL1 in cancer progression, the mechanism of action of this molecule may also be applied to solid ...

Recursion (NASDAQ:RXRX) reported early data from its AI-designed CDK7 inhibitor ... with rapid absorption, controlled target engagement, and favorable safety. The study observed one partial ...